CUTIA-B(02487): CU-20401 (recombinant mutated collagenase) completes Phase II clinical trial for treating submental fat accumulation in China.

CUTIA-B (02487) announced that the group has completed Phase II clinical trials of a potential new drug, CU-20401 (recombinant mutated collagenase), for the treatment of submental fat accumulation in China. The clinical trials showed that CU-20401 demonstrated significant and robust therapeutic advantages with good safety. The clinical trial was a multicenter, randomized, double-blind, and placebo-controlled trial designed to evaluate the efficacy and safety of CU-20401 in patients with moderate to severe submental fat accumulation. A total of 108 subjects were included in the trial and were randomly assigned to three groups in a 1:1:1 ratio - the low-dose CU-20401 group, the high-dose CU-20401 group, and the placebo control group. All three groups received a single dose and had a 100% compliance rate with medication.